Skip to content

News

News and events as they happen

Azurity News & Events
For media inquiries email: media@azurity.com

Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of One Lot of Firvanq® (vancomycin hydrochloride for oral solution), Vancomycin 50 mg/mL Kit, Due to a Mix-Up of the Diluent Included in the Kit

FOR IMMEDIATE RELEASE – September 7, 2021 – Wilmington, MA, Azurity Pharmaceuticals, Inc. (“Azurity”) is voluntarily recalling one lot of Firvanq® (vancomycin hydrochloride for oral solution), Vancomycin 50 mg/mL Kit (“Firvanq®”) to the consumer level, as some products in the affected lot have been found to incorrectly contain a First Omeprazole (FIRST-PPI) diluent instead of the Firvanq diluent bottle.

read more

Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals

NovaQuest Private Equity to support the continued growth of the combined innovative, patient-centric company
WOBURN, MA & ATLANTA, GA (August 24, 2021) – Azurity Pharmaceuticals, Inc. (“Azurity”) and Arbor Pharmaceuticals, Inc. (“Arbor”) today announced they have entered into a definitive agreement in which Azurity will be acquiring Arbor from

read more

Azurity Pharmaceuticals Announces Three New Neurology Products

WOBURN, Mass. (February 8, 2021) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today the purchase of the neurology portfolio from Eton...

read more

CutisPharma Announces FIRVANQ™

WILMINGTON, Mass. (Apr. 2, 2018) – CutisPharma announced today the commercial launch of FIRVANQ ™ (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including...

read more

NovaQuest Capital Management Acquires CutisPharma, Inc.

WILMINGTON, Mass. (Mar. 26, 2018) – CutisPharma, Inc. (“CutisPharma”), a specialty pharmaceutical company that for two decades has been the industry leader in providing innovative solutions to pharmacists, with its recently approved 505(b)(2) NDA for FIRVANQ ™...

read more

CutisPharma announces FDA approval of FIRVANQ™

CUTISPHARMA ANNOUNCES FDA APPROVAL OF FIRVANQ™ FOR TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA (CDAD) AND STAPHYLOCOCCUS AUREUS COLITIS FDA-approved vancomycin oral liquid therapy expected to improve patient access and reduce pharmacist burden by no longer...

read more

Arbor News & Events